Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus
Scott E. Guimond(Keele University), Jeremy E. Turnbull(University of Copenhagen), Alexander A. Khromykh(The University of Queensland), Julia A. Tree(UK Health Security Agency), Naomi S. Coombes(Public Health England), Marcelo A. Lima(Keele University), Alberto A. Amarilla(Commonwealth Scientific and Industrial Research Organisation), David G. Fernig(University of Liverpool), Daniel Watterson(The University of Queensland), Edward Trybala(University of Gothenburg), Dunhao Su(University of Liverpool), Courtney J. Mycroft‐West(Rosalind Franklin Institute), Edwin A. Yates(University of Birmingham), Vito Ferro(The University of Queensland), Tomas Bergström(Sahlgrenska University Hospital), Keith Dredge, Yin Xiang Setoh(Takeda (Singapore)), Edward Hammond(American Cancer Society), Miles W. Carroll(Institute of Human Genetics), Paul R. Young(Kent State University), Joanna Said(University of Gothenburg), Neha S. Gandhi(Queensland University of Technology), Kristina Nystrôm(University of Gothenburg), De Jun Julian Sng(The University of Queensland), Naphak Modhiran(The University of Queensland), Mohit Chhabra(The University of Queensland), Karen R. Buttigieg(Bradford Teaching Hospitals NHS Foundation Trust), Mark A. Skidmore(Keele University)
Unknown
June 24, 2020
Cited by 16
Related Papers
Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples
|Nature Protocols|2017|1.3k
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
|Cell|2021|1.2k
Animal models for COVID-19
|Nature|2020|877
Antibody evasion by the P.1 strain of SARS-CoV-2
|Cell|2021|661